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Abstract
Genome reduction is a hallmark of obligate intracellular pathogens such as Chlamydia, where adaptation to intracellular
growth has resulted in the elimination of genes encoding biosynthetic enzymes. Accordingly, chlamydiae rely heavily on the
host cell for nutrients yet their specific source is unclear. Interestingly, chlamydiae grow within a pathogen-defined vacuole
that is in close apposition to lysosomes. Metabolically-labeled uninfected host cell proteins were provided as an exogenous
nutrient source to chlamydiae-infected cells, and uptake and subsequent labeling of chlamydiae suggested lysosomal
degradation as a source of amino acids for the pathogen. Indeed, Bafilomycin A1 (BafA1), an inhibitor of the vacuolar H
+/
ATPase that blocks lysosomal acidification and functions, impairs the growth of C. trachomatis and C. pneumoniae, and these
effects are especially profound in C. pneumoniae. BafA1 induced the marked accumulation of material within the lysosomal
lumen, which was due to the inhibition of proteolytic activities, and this response inhibits chlamydiae rather than changes
in lysosomal acidification per se, as cathepsin inhibitors also inhibit the growth of chlamydiae. Finally, the addition of
cycloheximide, an inhibitor of eukaryotic protein synthesis, compromises the ability of lysosomal inhibitors to block
chlamydial growth, suggesting chlamydiae directly access free amino acids in the host cytosol as a preferred source of these
nutrients. Thus, chlamydiae co-opt the functions of lysosomes to acquire essential amino acids.
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Introduction
Intracellular bacterial pathogens must overcome a battery of
host cell mechanisms that block bacterial growth. One such hurdle
is phagolysosomal degradation, wherein the host cell directs
internalized bacteria into vesicle that is delivered to the acidic
lysosome for degradation. Accordingly, intracellular pathogens
have evolved mechanisms to avoid this process, including
diversion of the vesicle away from the endocytic pathway (e.g.,
Chlamydia [1] and Legionella [2]), lysing the vesicle and growing in
the cytosol (e.g., Rickettsia [3], Shigella [4], and Listeria [5]), delaying
or blocking the maturation of the phagosome (e.g., Mycobacterium
[6], and Salmonella [7]) or using the acidified environment as a cue
for growth and development (e.g., Coxiella [8], and Brucella [9]).
Collectively, these data have led to the prevailing dogma that
intracellular pathogens avoid, disrupt, or subvert the lysosome.
However, there is a dearth of information regarding how
organisms such as chlamydiae, which reside in a membrane-
bound vacuole, acquire essential nutrients and how they interact
with the lysosome.
Chlamydiae are obligate intracellular bacterial pathogens that
cause a broad spectrum of diseases in humans and animals. For
example, Chlamydia trachomatis (Ctr) is the leading cause of bacterial
sexually transmitted diseases in developed countries [10] and of
preventable blindness (trachoma) in developing nations [11].
Further, C. pneumoniae (Cpn) causes community-acquired pneumo-
nia and other respiratory tract diseases [12]. More importantly,
these pathogens cause chronic sequelae when not diagnosed or left
untreated, where Ctr infections lead to pelvic inflammatory
disease, tubal factor infertility [13], and reactive arthritis [14],
and where Cpn infections may lead to atherosclerosis [15], adult-
onset asthma [16], and other chronic conditions [17].
These highly successful pathogens utilize a biphasic life cycle that
alternates between an infectious extracellular, but metabolically
inert, elementary body (EB) and a non-infectious intracellular, but
metabolically active, reticulate body (RB) (for review see [18]).
Followingattachmentto asusceptible hostcell the EBisinternalized
by pathogen-directed processes into a vesicle that is then rapidly
modified to avoid lysosomal fusion. Specifically, shortly after uptake
theEBdifferentiates totheRB,whichthen growsanddivideswithin
the diverted vesicle. This modified vacuole, termed an inclusion,
contains chlamydial-derived proteins in its membrane. Chlamydiae
subvert various host cell processes that allow the bacteria to survive
inthecellandtoexpandtheinclusionasRBsmultiply.Finally,inan
asynchronous manner, RBs differentiate back to EBs, which are
then released from the host cell.
Host cell interactions with the inclusion have been frustratingly
difficult to identify. The chlamydial inclusion is a neutral pH
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compounds as small as 520 Da [20]. Previous studies have
suggested that chlamydiae do not depend on endosomal
acidification for growth, as no effects on inclusion formation were
detected in the presence of acidification inhibitors [1,21]. Further,
markers of the endocytic pathway (e.g., EEA-1, Rab5, Rab7, and
LAMP1/2; [22]) are not associated with the inclusion. Rather,
Chlamydia appears to insert itself into exocytic and recycling
pathways as it is can intercept sphingomyelin- [23] and
cholesterol- [24] containing vesicles and since the inclusion co-
localizes with markers of recycling endosomes [22]. However,
nascent host cell-derived proteins have not been detected in the
inclusion membrane, suggesting that Chlamydia exploits as yet
undefined trafficking pathways [25]. This is supported by findings
that disrupting exocytic pathways does not inhibit chlamydial
growth; thus, other pathways are used to obtain nutrients.
It has been assumed that chlamydiae acquire nutrients from the
host cell by directly transporting free amino acids, nucleotides, and
other small molecules, or that they acquire these and possibly other
nutrient sources from exocytic vesicles. Diverting the free amino acid
pool to the chlamydiae by inhibiting de novo host protein synthesis
enhances pathogen growth, suggesting chlamydiae preferentially rely
on the transport of free amino acids into the inclusion rather than
intercepting vesicles to acquire these nutrients [26,27]. We reasoned,
by virtue of its degradative functions, that the lysosome serves an
obligate role for chlamydiae - that of a source of amino acids. Here,
we report that Chlamydia indeed require lysosomal proteases and
lysosomal-mediated degradation of exogenous proteins for intracel-
lular growth, even under growth conditions in which free amino acids
were present in the extracellular medium, ready for transport. Thus,
the growth inhibitory effects observed in chlamydiae were not due to
the failure to replenish the cytosolic pool of amino acids. Rather, it is
likely due to the depletion of amino acids and/or oligopeptides within
the lysosomal compartments. Additionally, we show a marked
difference between chlamydial species and strains and that their
requirement for lysosomal activity depends on their growth rate,
where the slowest growing species and strains are the most dependent
on the lysosome. These findings support a model whereby the
degradation of cargo derived from the endocytic pathway by the
lysosome provides essential nutrients for growth of Chlamydia.
Results
The chlamydial inclusion is in close apposition to
lysosomes throughout the developmental cycle
Chlamydial inclusions localize to the microtubule organizing
center (MTOC; [28]). Interestingly, lysosomes also localize to the
perinuclear region of the cell, and thus we investigated the relative
subcellular localization of chlamydial inclusions and their associa-
tion with lysosomes. To monitor lysosomal morphology and
localization, HEp-2 cells were transfected with a vector driving
the expression of LAMP1-YFP, a lysosomal transmembrane protein
fused in-frame with yellow fluorescence protein (YFP), and these
cells were then infected with Ctr and assessed for their localization
by confocal microscopy. Strikingly, chlamydial inclusions were
always found in close proximity to lysosomes throughout their
developmental cycle (Fig. 1), although the LAMP1-YFP marker
never co-localized to the inclusion membrane [1].
Lysosomal degradation products are transferred to
chlamydiae
Given the close apposition of chlamydial inclusions to lysosomes
during the developmental cycle, we hypothesized that lysosomal
proteolytic activity, which catabolizes polypeptides to oligopep-
tides and free amino acids, may be a nutrient source for Chlamydia.
It is well known that lysosomal and fluid phase markers are not
transferred to the inclusion [1,20], yet lysosomes do generate
degradative products, such as oligopeptides for which chlamydiae
have specific transport systems [29,30]. To determine if such a
transfer could occur, we assessed the ability of pre-labeled proteins
to be incorporated into chlamydiae following lysosomal digestion.
Click-iTH chemistry was employed, where newly synthesized
proteins are metabolically labeled with the amino acid analogue
azidohomoalanine (AHA) in place of methionine using AHA-
supplemented methionine-free medium. AHA-containing proteins
can be detected using a fluorescent alkyne-containing ligand, and
Figure 1. The chlamydial inclusion is in close apposition to lysosomes throughout its developmental cycle. Cells were transfected with
LAMP1-YFP (green) and were infected with Chlamydia trachomatis serovar L2 (red) or left uninfected (UI). At indicated times post-infection, cells were
fixed and stained for chlamydiae. Arrowhead indicates an early chlamydial inclusion.
doi:10.1371/journal.pone.0016783.g001
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macromolecules occurs in the presence of copper catalysts [31].
Infected cells were fed with an AHA-labeled uninfected cell lysate,
from which free AHA amino acids had been removed by filtration.
Efficiency of removal of the free AHA amino acids by filtration
was determined by spiking unlabeled lysates with free AHA and
examining the amount of label associated with Cpn-infected cells.
Under this condition, labeling was minimal (data not shown). The
cells were fixed and processed for secondary labeling. Notably,
AHA was easily visualized within chlamydial inclusions (Fig. 2).
Cpn inclusions were uniformly labeled with AHA derived from
pre-labeled protein whereas Ctr L2 inclusions were not consis-
tently labeled. Not surprisingly, host cells were also labeled, as they
endocytosed the protein lysate and metabolized its products, and
the extracellular protein lysate was also visible. These data
demonstrate for the first time that labeled amino acids and/or
oligopeptides generated within the lysosome are transferred to
chlamydiae. Furthermore, there is a species-dependent utilization
of lysosomal pools of oligopeptides/amino acids, with C. pneumoniae
acquiring a greater amount of label than C. trachomatis.
Compromising lysosomal functions impairs chlamydial
growth
The ability of Chlamydia to acquire lysosomal degradation
products was surprising given previously published observations
suggesting disruption of lysosomal activity has no effect on
chlamydial growth [1,21,32]. Thus, we initiated studies to
carefully assess whether lysosomal functions were required for
chlamydial growth by three independent approaches that provide
increasing specificity – a) inhibiting the vacuolar H
+/ATPase by
Bafilomycin A1 (BafA1) to disrupt the acidic environs and pH-
dependent functions of the lysosomes; b) inhibiting the activity of a
subset of lysosomal cathepsins using the CathInIII cathepsin
inhibitor; c) depleting cells of TFEB, a regulator of cathepsin gene
expression. All of these experiments were conducted in media
supplemented with free amino acids to ensure that the cytosolic
pool would not be depleted.
Bafilomycin A1. The relatively broad specificity and
potential cytotoxicity of BafA1 warranted a series of control
experiments. Therefore, the increase in lumenal pH, effects on
other trafficking events, namely sphingomyelin transport to the
inclusion, and cytotoxicity to the host cells were carefully
monitored, with the last by microscopy and fluorescence
activated cell-sorting analysis of cell death by apoptosis (Annexin
V) and loss of plasma membrane integrity (propidium iodide).
Data from all of the control experiments, which involved
treatment with 50 nM or 100 nM BafA1 and with a final
DMSO concentration of 0.1%, indicated that BafA1 was indeed
able to inhibit acidification (Fig. 3A), trafficking events known to
be relevant to Chlamydia (i.e. transport of sphingomyelin from the
trans-Golgi) appeared unaffected (Fig. 3C), and the levels of
cytotoxicity observed were negligible (Fig. 3B). Additionally,
treatment with BafA1 resulted in the accumulation of
undegraded materials in the lysosomes (Fig. 3D).
The effects of BafA1 treatment on the growth of Chlamydia,
specifically C. trachomatis LGV serovar L2 were evaluated in a dose-
response experiment, with BafA1 concentrations ranging from 0 to
100 nM (Fig. 4A). Ctr L2 was chosen because it was one of the
least fastidious strains, and thus any effects observed with this
serovar would likely be reproducible in more fastidious ones. It is
clear that at the lowest dose of 10 nM, a statistically significant
reduction in the yield of infectious elementary bodies could be
observed, with higher levels of inhibition consistently observed
with increasing BafA1 concentration. Thus, lysosomal acidification
appears to be necessary for chlamydial growth. We observed a
similar inhibition of chlamydial growth in cells treated with the
lysosomotropic agent chloroquine (data not shown).
A direct comparison of relative susceptibility to BafA1 treatment
between C. trachomatis and C. pneumoniae was conducted (Fig. 4B).
Because of the different growth rates of the two chlamydial species,
experiments that varied the treatment of cells with BafA1 relative to
the time of infection were conducted to assess the temporal
requirement by chlamydiae for lysosomal function, as well as to
allow for a more detailed comparison of their relative susceptibilities.
Figure 2. Lysosomal degradation products are transferred to chlamydiae. AHA-labeled protein was fed to infected cells, and cells were
subsequently fixed and processed for confocal microscopy. Chlamydiae were counter-stained with an antibody to facilitate identification of AHA label
within chlamydiae. For Ctr, arrowheads indicate individual organisms positive for labeling with AHA whereas for Cpn, arrowheads indicate inclusions
with multiple organisms. Note the intensity of the stain in the zoomed insets and the more uniform staining of Cpn organisms compared to Ctr.
Bright staining on the cell surface is AHA-labeled protein lysate that was not endocytosed.
doi:10.1371/journal.pone.0016783.g002
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with BafA1 and IFU recovery was quantified. When 100 nM BafA1
was added at the time of infection, IFU recovery from Cpn-infected
cells at 48 hr post-infection (p.i.) was reduced .99.5% or nearly 3-
logs, whereas recovery from Ctr serovar L2-infected cells at 24 hr p.i.
was reduced by approximately 90% (Fig. 4B).
Because the growth cycle of Cpn is 72–96 hours, we tested
whether lysosomal functions were solely required for initial events
following uptake of the EB or if this dependence was necessary
throughout the developmental cycle. To this end, we delayed
addition of BafA1 until 24 hr p.i. and then measured Cpn IFU
recovery at 48 hr p.i. Under this scenario Cpn growth was still
inhibited greater than 100-fold (Fig. 4B); thus, Cpn requires
proper function of the endo/lysosomal system throughout its
developmental program. Its greater sensitivity to BafA1 treatment
relative to Ctr may reflect its greater reliance on the lysosome for
nutrients.
Ctr completes its developmental cycle in approximately 48 hr,
suggesting that the relative resistance of Ctr to BafA1 treatment
could be accounted for in part by its more rapid growth. To test
this notion, we pre-treated cells for at least one hour with BafA1
prior to infecting with Ctr, and then measured EB production at
24 hr p.i. Interestingly, Ctr growth was markedly diminished by
pre-treatment with BafA1 (Fig. 4B). By varying the time of
treatment, we discovered that proper lysosomal acidification is
critical during the early life cycle of Ctr but is dispensable at later
stages of development, whereas Cpn requires properly acidified
lysosomes throughout its developmental cycle.
Figure 3. Bafilomycin A1 (BafA1) has selective effects on the host cell. (A) LysoTracker
TM Red staining of untreated (UTD) or 100 nM BafA1-
treated HEp-2 cells for the indicated times. Bar represents 10 mm. (B) Cell viability was measured by flow cytometry of Annexin/PI stained cells.
Viability of uninfected and Cpn-infected cells +/2 100 nM BafA1 (top) and of uninfected and Ctr-infected cells +/2 100 nM BafA1 (bottom). (C) BafA1
does not disrupt uptake of fluorescent sphingomyelin by chlamydiae during BafA1 treatment. Cells were infected with Ctr L2 and pulsed with
fluorescent ceramide, which is converted to sphingomyelin in the Golgi and subsequently transported by the exocytic pathway. Images were
acquired at 6306magnification on an epifluorescent microscope. (D) Ultrastructural analysis of untreated and BafA1-treated uninfected HEp-2 cells.
Note the presence of enlarged vesicular structures that contain undigested materials. Scale bar equals 1 mm.
doi:10.1371/journal.pone.0016783.g003
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be related to acquisition of nutrients from the lysosome, as hinted
by the labeling experiment (Fig. 4C), we performed an electron
microscopic analysis of infected cells. We reasoned that nutrient
deprivation should result in the establishment of aberrant
reticulate bodies within intact inclusions [33]. Also, within the
same cells, enlarged lysosomes filled with undigested material in
BafA1-treated cells should be apparent. In untreated cells Cpn
inclusions were readily detected with many RBs and some
intermediate forms characteristically filling the inclusion space at
48 hr p.i. (Fig. 4C). Likewise, characteristic Ctr L2 inclusions were
evident with bacteria juxtaposed to the inclusion membrane
(Fig. 4C). Treatment with BafA1 led to a massive accumulation of
undigested material within the lumen of lysosomes, which then
swelled (Fig. 4B and D). Treatment with BafA1 completely
abolished Cpn inclusion formation (Fig. 4C), demonstrating the
requirement for a functional lysosome in the growth of this
organism. In contrast, Ctr L2 inclusions were readily detected in
Figure 4. Impairing lysosomal functions blocks growth of Chlamydia. (A) IFU recovery of Ctr serovar L2 from cells treated with the indicated
doses of BafA1. (B) 100 nM BafA1 was added to Cpn or Ctr at different times relative to infection: toi = time of infection, pi=24 hr post-infection,
pt=24 hr pre-treatment. For IFU recovery experiments, data were pooled from at least three independent experiments with the average and
standard deviation shown in percentage of the untreated control. Two-tailed Student’s t tests assuming equal variance were performed for each
experiment and p values combined using Fisher’s Test for Combining p values. * indicates p,0.0001 for treatments compared to untreated control.
(C) Ultrastructural analysis of untreated and BafA1 (100 nM)-treated Cpn- or Ctr-infected cells. Arrow indicates lysosome with undegraded material.
Bars for cells infected with Cpn only (A and B) represent 2 mm whereas all others represent 1 mm. (D) BafA1 does not induce an anti-chlamydial
effector. Cells were infected first with Cpn and then with Ctr to determine if Ctr could protect Cpn during BafA1 treatment, which would suggest a Ctr
secreted factor in allowing growth. Arrow indicates Cpn inclusion whereas arrowhead indicates Ctr inclusion. The bottom panel shows a cell
co-infected with Cpn- and Ctr L2 and treated with BafA1, with only a distinguishable Ctr inclusion present.
doi:10.1371/journal.pone.0016783.g004
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were somewhat enlarged, suggesting impaired or delayed growth
[33]. Finally, these effects correlated with the accumulation of
undigested material in lysosomes, further suggesting that chla-
mydiae require the degradation of material within the lysosome for
optimal growth. The failure to detect even abnormal inclusions
suggests Cpn require lysosomal activity at early stages of infection.
That inclusions from Ctr, but not Cpn, were evident in BafA1-
treated HEp-2 cells indicated that Ctr can partially overcome the
effects of BafA1 and might produce a secreted factor that
contributes to this resistance. To test this hypothesis, we assessed
Cpn inclusion formation in co-infected cells treated with BafA1.
Strikingly, after BafA1 treatment, only Ctr inclusions were
apparent (Fig. 4D). Therefore, while Ctr is partially resistant to
the effects of BafA1, this resistance does not allow Cpn growth in
the presence of BafA1.
Cathepsin inhibitor. To refine further the results obtained
from BafA1 treatment, we focused on a more specific aspect of
lysosome function – proteolysis. Optimal activity of lysosomal
proteases requires an acidic pH [34], and we hypothesized that the
growth inhibitory effects of BafA1 on chlamydiae were simply due
to the inhibition of lysosomal proteolysis. To test this, lysosomal
proteolytic functions were compromised using an inhibitor of a
subset of lysosome-associated cathepsins, Cathepsin Inhibitor III,
which inhibits the lysosomal cysteine proteases cathepsins B, L,
and S. Infected cells were treated with this cathepsin inhibitor and
were then monitored for IFU recovery. This inhibitor did not
affect lysosomal acidification (Fig. 5A). Thus, the growth inhibitory
effects on chlamydiae of BafA1 could be linked directly with the
inhibition of cathepsin activity, which is optimal at acidic pH.
Notably, Cathepsin Inhibitor III blocked the growth of both Ctr
L2 and Cpn, albeit somewhat less efficiently than BafA1 (Fig. 5B).
Thus, the growth inhibitory effects on chlamydiae of BafA1 could
be linked directly with the inhibition of cathepsin activity, which is
optimal at acidic pH. The differences in the degree of chlamydial
growth inhibition resulting from BafA1 and Cathepsin Inhibitor
III treatments may reflect the continued activity of other lysosomal
proteases that fall outside the target spectrum of the cathepsin
inhibitor. There are ten cathepsins encoded in the human genome
[35], and thus, functional redundancies and/or compensatory
activities likely explain the lower degree of inhibition by Cathepsin
Inhibitor III, which targets cathepsins B, L, and S. Regardless, it
can be concluded from the data that both Ctr and Cpn require
lysosomal proteases.
TFEB knockdown. A recent report identified TFEB as a
master transcriptional regulator of lysosomal biogenesis and
function [36]. Specifically, TFEB is necessary to induce the
expression of cathepsins and many other genes required for the
development and function of the lysosome (Fig. 6A). By contrast,
BafA1 acts to disrupt the intralumenal environment of the
lysosome to inhibit its function. Therefore, we tested whether
depletion of TFEB by siRNA would impair chlamydial growth.
Greater than 75% selective knockdown of TFEB mRNA
expression was achieved (Fig. 6B), and the levels of TFEB
target CtsD encoding for cathepsin D were reduced by ,50%
(Fig. S1). Effects of TFEB knockdown were tested on Ctr serovar
B, which grows more slowly and would thus be more likely to
show an effect over the course of TFEB knockdown. Although
there was a trend towards smaller and fewer inclusions in TFEB
knockdown cells, the degrees of variation between independent
trials fluctuated enough to affect statistic significance. TFEB
knockdown had little effect on the yield of infectious particles
(Fig. 6C). However, any hidden effects of TFEB knockdown were
revealed by the addition of a sub-inhibitory dose (5 nM) of
BafA1, which is 10- to 20-fold less than the doses used in the
above experiments (Fig. 6C). It is possible that any effects on the
lysosomes of a partial knockdown of TFEB expression
compromised these organelles to a degree that rendered them
more susceptible to a sub-inhibitory dose of BafA1.
Collectively, the different approaches used to affect lysosomal
function with increasing specificities all inhibited the growth of
Chlamydia, thus indicating a growth requirement by the pathogen
for this degradative organelle.
Autophagy, the cytosol, and the lysosome as potential
sources of amino acids for chlamydia
To implicate the lysosome in nutrient acquisition by Chlamydia,
we decided to manipulate three potential sources of amino acids in
the cell – autophagy, the cytosol, and the lysosome. Shifting the
balance from one source to the other may provide insights into
utilization of these amino acid reservoirs.
The autophagy pathway. The lysosome is the nexus for
degradation of both intracellular and extracellular proteins.
Intracellular proteins can be delivered to lysosomes through a
double-membrane vesicle called an autophagosome, whereas
extracellular material is endocytosed and delivered to lysosomes
through the endocytic pathway. Because of the intersection of
these two pathways at the lysosome, nutrient pools derived from
both would be susceptible to BafA1 treatment. Indeed, BafA1
effectively blocked both pathways, as cells treated with BafA1 had
a marked accumulation of endocytosed BSA (data not shown) as
well as LC3 (microtubule light chain 3), a protein that is both
required for and degraded by the autophagy pathway [37] (Fig. 7A
and 7B). The ability of BafA1 to block lysosomal-directed turnover
of LC3 implies that it blocks other autophagy protein substrates, as
least those of acid-activated proteases such as cathepsins. Since
BafA1 abolished degradation of autophagic and endosomal cargo
by the lysosome, we tested the role of autophagy in chlamydial
growth, which has been suggested by others as necessary for
growth of this pathogen [38]. To this end we evaluated the growth
of Ctr in primary, early passage mouse embryonic fibroblasts
(MEFs) lacking Atg7, an E1 enzyme that is essential for
autophagosome formation [39], or paired wild-type MEFs.
These studies were limited to Ctr, as Cpn does not grow in
mouse cells [40]. Paired Atg7
+/+ and Atg7
2/2 MEFs were infected
and either left untreated or were treated with 50 nM BafA1.
Notably, Ctr L2 grew equally well in both wild type and Atg7
2/2
MEFs, and BafA1 treatment led to a 0.5 log difference in IFU for
both lines compared to untreated cultures (Fig. 7C). Thus, Atg7
and autophagy are dispensable for chlamydial growth under
conditions in which other sources of amino acids are intact. This
observation is in agreement with others using Atg5 knockout cells
[41].
The cytosol. The more fastidious chlamydial species and
strains grow more slowly than others, and blocking eukaryotic
protein synthesis with agents such as cycloheximide or emetine
augments their growth [26,27]. These observations were
attributed to the elimination of competition from the host, with
these agents effectively raising the pool of free amino acids that
chlamydiae can access. We reasoned that increasing the cytosolic
free amino acid pool, which is replenished by de novo biosynthesis
and uptake from the extracellular environment via pinocytosis or
import by specific transporters, would compensate for the loss of
lysosome-associated oligopeptide/amino acid pools resulting from
BafA1 or Cathepsin Inhibitor III treatment in infected cells. We
therefore tested whether treatment of infected host cells with 1 mg/
ml cycloheximide could override the inhibitory effects of BafA1
and Cathepsin Inhibitor III on the growth of Ctr and Cpn.
Lysosomal Degradation and Chlamydial Growth
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48 hr p.i. for Cpn and at 24 hr p.i. for Ctr L2. Cycloheximide did
not restore lysosomal acidification in BafA1-treated cells as
visualized by Lysotracker (data not shown). Remarkably,
cycloheximide treatment rescued chlamydial growth in the
presence of BafA1, and these effects were more profound for
Cpn than for Ctr (Fig. 8A and 8B). A parallel immunofluorescence
confocal images of the various experiment groups demonstrates
the enhancing effects of cycloheximide on inclusion sizes of
chlamydiae treated with BafA1 (Fig. 8C). The inhibitory effects of
Cathepsin Inhibitor III on the growth of Cpn and Ctr were also
reversed with cycloheximide. Thus, both chlamydial species have
the ability to acquire free amino acids from the host, and for Cpn,
this ability only becomes obvious when the host cell was prevented
from utilizing the same pool. Taken together, the results indicate
that chlamydiae have at least two sources of amino acids – those
derived from within the lysosome and those that are transported
from the extracellular environment into the host cytosol. Under
conditions in which these two sources are intact, autophagy, likely
the constitutive microautophagy, has minimal, if any role, in
chlamydial growth. The ability of Cpn to grow and survive, in
spite of its relatively poor ability to compete with the host cell for
the cytosolic pool of amino acids compared to Ctr L2, is suggestive
of its greater reliance on the lysosome.
Exogenous delivery of BSA preferentially supports
growth of C. pneumoniae in infected host cells deprived
of amino acids
The data presented so far, which showed higher levels of AHA
signal in Cpn inclusion within cells fed AHA-labeled polypeptides,
sensitivity to BafA1 and Cathepsin Inhibitor III treatments, and
enhancement of growth when the cytosolic pool of amino acids
was liberated by cycloheximide treatment, suggested that Cpn is
more dependent on lysosome-mediated degradation of proteins as
a source of amino acids. To examine this greater dependency, we
took advantage of the well-established observation that exogenous
polypeptides, like horseradish peroxidase and bovine serum
albumin are taken up and trafficked to the lysosome where they
Figure 5. Cathepsin proteolytic activity is required for optimal growth of Chlamydia. (A) LysoTracker
TM Red staining of untreated or 75 mM
Cathepsin Inhibitor III-treated HEp-2 cells for the indicated times. Bar represents 10 mm. (B) Cathepsin Inhibitor III compromises chlamydial growth.
This cathepsin inhibitor was titrated for its effect and was used at 40 mM. For IFU recovery experiments, data were pooled from at least three
independent experiments with the average and standard deviation shown in percentage of the untreated control. Two-tailed Student’s t tests
assuming equal variance were performed for each experiment and p values combined using Fisher’s Test for Combining p values. * indicates
p,0.0001 for treatments compared to untreated control.
doi:10.1371/journal.pone.0016783.g005
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endocytosis of exogenous proteins should support chlamydial
growth. Thus, this experimental system is directly examining the
role of the lysosome in providing amino acids/oligopeptides to
chlamydiae in the absence of other sources and independent of
pharmacological agents. To test this, infected cells were cultured in
normal medium (with amino acids, glucose, and fetal calf serum),
Hank’s balanced salt solution (HBSS, no amino acids but normal
levels of glucose), HBSS supplemented with 5% BSA (bovine
serum albumin), or normal medium lacking serum (iIMDM).
Importantly, the BSA used for these studies lacked free amino
acids, as it was purified by alcohol precipitation, and there was no
partial proteolysis as assessed by SDS-PAGE and Coomassie
staining (data not shown). HEp-2 cells grown in all of these
conditions were similarly competent for fluid phase uptake as
demonstrated by dextran labeling (data not shown). As expected,
Figure 6. TFEB knockdown and sub-inhibitory doses of BafA1 block chlamydial growth. (A) Schematic of the role of TFEB in controlling
lysosomal function. (B) Fold change in TFEB expression normalized to endogenous control 18S rRNA expression in un-transfected (UTD), negative
control siRNA transfected (Neg), mock-transfected (Mock), or TFEB siRNA transfected cells. Data represent 3 pooled experiments performed in
triplicate. (C) Measurement of IFU recovery during transfection in the presence and absence of a sub-inhibitory dose (5 nM) of BafA1. Data represent
at least 3 pooled experiments performed in triplicate. * indicates p,0.02 vs. all conditions.
doi:10.1371/journal.pone.0016783.g006
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HEp-2 cells in the absence of amino acids. Only aberrant RB
forms were detected in small inclusions (Fig. 9A and 9B, and data
not shown). However, when supplemented with BSA, Cpn growth
was partially restored as shown by the formation of infectious EBs.
In contrast, BSA supplementation did not enhance Ctr L2 growth
in HBSS. When growth was assessed in medium containing amino
acids, but lacking exogenous peptides (i.e., no serum), Ctr grew
significantly better than Cpn (Fig. 9B). Since Cpn grows better in
media supplemented with BSA than Ctr, we concluded that Cpn
preferentially relies upon protein degradation for growth. This is
quite remarkable given the sub-optimal ratio of amino acids that
compose the BSA polypeptide compared to the amino acids
present in the cell-culture optimized iIMDM.
Because depletion of amino acids and serum could provoke host
cell death, we also monitored cell viability as above. The effects of
amino acid depletion (cells cultured in HBSS +/2 BSA) and the
withdrawal of serum had modest effects on cell viability, which in
all cases was greater than 70% by the completion of the
experiments (Fig. 9C). Thus, the decrease in IFU recovery reflects
diminished nutrient supplies for the chlamydiae as opposed to cell
death. Because BSA could only be taken up by micro- and
Figure 7. Autophagy is not a required source of nutrients for Chlamydia. (A) Western blot analyses demonstrated a marked accumulation of
LC3 in BafA1-treated (100 nM) cells. Equal loading was confirmed by immunoblot with anti-actin antibody. (B) BafA1 treatment induced the
accumulation of GFP-LC3 localized to vesicular structures in HEp-2 cells. (C) IFUs recovered from Ctr L2-infected, paired Atg7
+/+ or Atg7
2/2 MEFs that
were left untreated (UTD) or were treated with BafA1 (50 nM). Data were pooled from three experiments performed in triplicate with the mean and
standard deviation shown. Two-tailed Student’s t tests assuming equal variance were performed for each experiment and p values were combined
using Fisher’s Test for Combining p values (* indicates p,0.005 for comparisons of treated and untreated cells). There was no significant difference in




Lysosomal Degradation and Chlamydial Growth
PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e16783macropinocytosis, the restoration of Cpn growth could be
explained parsimoniously by the transport to the lysosome of
BSA for degradation and subsequent generation of amino acids
and oligopeptides for chlamydial utilization.
The preferences of Cpn versus Ctr for sources of amino acids
was also investigated by labeling with azidohomoalanine (AHA) as
described above, either in the free form or incorporated into
polypeptides prepared from cells incubated with this methionine
homologue. Labeling with free AHA amino acid led to greater
fluorescence signal appearing in Ctr inclusions versus Cpn
inclusions (Fig. 9D). In contrast, labeling with AHA-labeled
polypeptides yielded greater fluorescence within Cpn inclusions
compared to Ctr inclusions (Fig. 9E).
This analysis was also applied to a Ctr/Cpn co-infection model,
where we directly compared the ability of the two chlamydial
species to obtain oligopeptides/amino acids in co-infected cells.
HEp-2 cells were first infected with Cpn, followed by Ctr infection
at 24 hr p.i. The infected monolayer was incubated with free AHA
or AHA-labeled polypeptides prepared from labeled cell lysates
and the samples were processed for Click-iT detection and
subsequent confocal microscopy. Notably, within the same
monolayer and in some cases within the same cell, Ctr inclusions
were labeled more efficiently by free AHA than by AHA-labeled
polypeptide (Fig. 9F). Furthermore, in direct comparison with Cpn
inclusions (arrowheads, Fig. 5F), those of Ctr (arrows, Fig. 5F) had
higher levels of label. This is in contrast to Cpn inclusions, which
showed an opposite labeling profile and a clear preference for
AHA-labeled polypeptides. Thus, Ctr and Cpn have inherent
differences in the way their amino acid requirements are satisfied.
Discussion
We have explored the potential role of the lysosome as a source
of nutrients, specifically of oligopeptides and/or amino acids, in
Figure 8. Cycloheximide rescues Chlamydia from the growth inhibitory effects of BafA1 and Cathepsin Inhibitors. IFUs recovered from
(A) Cpn- or (B) Ctr L2-infected cells treated with BafA1 (100 nM) or Cathepsin Inhibitor III (40 mM) +/2 cycloheximide (1 mg/ml) are shown. Data were
pooled from at least three experiments performed in triplicate, with the mean and standard deviation shown as the percentage of the untreated
control. Two-tailed Student’s t tests assuming equal variance were performed for each experiment and p values combined using Fisher’s Test for
Combining p values (* indicates p,0.05 for cycloheximide treatments compared to relevant sample). (C) Immunofluorescence images of Cpn and Ctr
inclusion in HEp-2 monolayers that were either untreated, BafA1-treated, or BafA1/cycloheximide-treated. Note the complete absence of mature Cpn
inclusions in BafA1-treated cells.
doi:10.1371/journal.pone.0016783.g008
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PLoS ONE | www.plosone.org 10 March 2011 | Volume 6 | Issue 3 | e16783Figure 9. Lysosomally digested material promotes chlamydial growth in amino acid-free medium. (A) IFUs recovered from Cpn-infected
cells grown in the indicated media are shown. (B) IFUs from Ctr L2-infected cells grown in the indicated media are shown. For (A) and (B), data were
pooled from at least three experiments performed in triplicate with the mean and standard deviation shown as the percentage of the untreated
control. Two-tailed Student’s t tests assuming equal variance were performed for each experiment and p values combined using Fisher’s Test for
Combining p values (* indicates p,0.0001 for comparisons to HBSS alone; + indicates that two of three experiments testing the effects of exogenous
BSA in Ctr infected cells were not significant). (C) Cell survival is not compromised by amino acid or serum deprivation. Viable cell numbers in the
different growth media were determined at the indicated intervals by trypan blue exclusion. Data were pooled from two experiments with the mean
and standard deviation shown. HBSS=Hank’s Balanced Salt Solution. BSA=5% BSA in HBSS. iIMDM=incomplete IMDM (lacking serum). (D–F) Amino
acid preferences of Ctr and Cpn as revealed by labeling with AHA amino acid or AHA-labeled protein lysate fed to infected cells and imaged by
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demonstrated the transfer of azidohomoalanine (AHA), a
methionine analog, to Chlamydia from metabolic labeling experi-
ments with two different precursors – free AHA and AHA
incorporated into polypeptides. Investigating the biological
relevance of such transfer using inhibitors of lysosomal acidifica-
tion and cathepsin proteases, and knockdown of a protein required
for lysosome biogenesis, approaches with increasing specificities,
revealed a role for this organelle in the growth of Ctr and Cpn,
albeit to different extents. Importantly, we made a novel
observation of the strain-dependent differences in co-opting amino
acid sources – via endosome-lysosome degraded exogenous
sources or pools of intracellular free amino acids.
Precisely how chlamydiae acquire nutrients from the infected
host cell, particularly amino acids, has been unclear as there are, as
established here, redundant pathways in operation. The host cell
satisfies its amino acid requirements through de novo biosynthesis,
transport of environmental amino acids via amino acid transport-
ers, and through degradation of polypeptides. The host cell resorts
to de novo synthesis using glucose as the precursor when
environmental sources fall below a threshold. In other words, it
is more energetically favorable to import pre-synthesized amino
acids or peptides. Replenishment of amino acid pools via
degradative pathways can be further classified with regard to the
source of the polypeptides. Exogenous polypeptides are endocy-
tosed and delivered to the lysosome where they are degraded by
acid-activated proteases to oligopeptides and amino acids. On the
other hand, endogenous polypeptides could be degraded by the
proteasome or are delivered to the lysosome by autophagosomes.
We observed the close proximity of chlamydial inclusions and
lysosomes. Based on this observation, we investigated the notion
that Chlamydia obtains amino acids and/or oligopeptides from this
organelle, which receives cargo from both endosomal and
autophagosomal pathways. Autophagy was discounted as chla-
mydiae grew equally well in autophagy competent and deficient
MEFs, and their growth was similarly impaired by BafA1
treatment of wild type and Atg7 knockout cells.
The principal mode by which lysosomal functions contribute to
chlamydial growth were revealed by both inhibitor and genetic
studies. Firstly, BafA1 or cathepsin protease inhibitors impaired
chlamydial growth, suggesting that the functions of acid-activated
cathepsins provide the necessary oligopeptides and/or free amino
acids for chlamydial growth. Secondly, knockdown of the host
master lysosomal transcription factor TFEB, a known transcrip-
tional activator of cathepsins [36], augmented the sensitivity of
chlamydiae to and blocked their growth when treated with sub-
inhibitory doses of BafA1. Collectively, these data implicate
lysosomal cathepsins as necessary proteases for chlamydial growth.
Ideally, this question would be addressed by RNA interference of
the cathepsins, but the number of cathepsin genes in the human
genome, of which there are ten [35], precludes such an approach.
Finally, the requirement for lysosomal cathepsin activity is
consistent with our studies showing transfer of exogenous pre-
incorporated AHA-labeled polypeptides into chlamydial inclusions
and that exogenous polypeptides could support the growth of
chlamydiae. Thus, it is likely that polypeptides trafficked to the
lysosome via the endosomal transport pathway are processed into
small molecular weight oligopeptides and/or amino acids that are
then transported out of the lysosome by specific transporters
[42,43], where they are sequestered by chlamydiae. It is important
to note that infected cells were grown in the presence of
extracellular amino acids, which could be transported by the host
cell to maintain its cytosolic amino acid pool. Therefore, effects on
growth inhibition of chlamydia by the different means of
modulating the degradative function of the lysosome were likely
due to the depletion of amino acids and/or oligopeptides within
the lysosomal compartments, and not due to the failure of the
lysosomes to replenish the cytosolic pool.
In what form are amino acids during uptake by Chlamydia? They
could be free or in the form of soluble oligopeptides, both of which
could be generated within the lumen of the lysosomes [42,43]. Our
data suggest Cpn utilizes the oligopeptide form as their growth was
restored by media supplemented with BSA even though the amino
acid composition of BSA is not ideal for chlamydial growth. This
apparent preference for oligopeptides was highlighted by the
observed relative inefficiency in acquiring free AHA amino acid.
The Cpn genome contains 14 genes encoding for oligopeptide and
dipeptide transporters [30]; hence this species has the capability of
taking up oligopeptides from the host cytosol. Because di- and tri-
peptides are less than 520 Da, they should freely diffuse through
the inclusion membrane [20] allowing these transporters to import
peptides from the inclusion lumen directly into the bacteria [45];
the proximity of inclusions to lysosomes increases the likelihood
that these peptides will be sequestered by chlamydiae.
Cpn also possess a number of amino acid transporters [30],
with their functionality demonstrated by the uptake of free AHA,
albeit less efficiently than Ctr. Therefore, its inability to grow
optimally in media supplemented with free amino acids may be
due to factors other than transporter functionality – factors that
may be related to growth rate and its ability to compete with the
host. This is in contrast to the faster growing Ctr, which has a
markedly different mode of amino acid utilization. Ctr was more
dependent on the lysosome at the early stages of infection, with
the establishment of larger and more mature inclusions
correlating with resistance to BafA1 treatment. During matura-
tion of the inclusion, we observed a nutrient switch from using
oligopeptides originating from the lysosome to amino acids from
the host cell cytosol, consequently conferring increasing indepen-
dence from the lysosome, and thus increased BafA1 resistance.
How this switch happens may be related to what is present within
EBs and what is expressed during EB-to-RB differentiation. For
example, DppA and DppD, components of a dipeptide
transporter, are found in elementary bodies of Ctr [45]. We
suspect that the reliance on the lysosome could be a way to
bypass the competition from the host cell imposed on the
chlamydiae. At early times in infection, an infecting EB,
regardless of the species, has a small complement of ribosomes
and would be at an immediate disadvantage to the host cell, and
dependence on the lysosomes for oligopeptides and/or amino
acids would overcome the competition at this stage of infection.
This was certainly true for both Cpn and Ctr, which we found to
be susceptible to BafA1 at the early stages of infection. With
sufficient time, increased numbers of metabolically active
chlamydial organisms would be poised to compete better with
confocal microscopy. (D) Pulse-labeling of chlamydiae with free AHA amino acid in the presence of cycloheximide. Note the weak labeling of Cpn
compared to Ctr. (E) Infected cells were fed AHA-labeled protein cell lysate in the absence of cycloheximide. Note the comparative levels of stain
between species. (F) Cells infected with both Cpn and Ctr were either pulse-labeled with free AHA amino acid or fed AHA-labeled protein cell lysate,
as above, to directly compare the relative labeling efficiencies between the species. For panels (D–F), organisms were counterstained with antibody
to facilitate visualization of organisms.
doi:10.1371/journal.pone.0016783.g009
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explains how chlamydiae obtain amino acids from the host.
Under normal conditions, fast-growing Ctr (with a division time
of approximately two hours [46]) effectively compete with the
host cell for amino acid pools and are thus less reliant on the
lysosomal degradation pathway. By contrast, slower-growing Cpn
(with a division time of approximately four hours [47]) are poor
at competing with the host cell for free amino acids and thus they
rely almost exclusively on the amino acids and peptide fragments
generated through lysosomal proteolysis. Consequently, in the
presence of BafA1, Cpn loses the primary source of amino acids
for which it is adapted and thus cannot grow whereas Ctr can still
utilize the free amino acid pools in the cytosol of the host.
Our data demonstrate the importance of lysosomal degradation
in supporting chlamydial growth. We recognize that our studies
challenge those of others who reported no effect of BafA1 on
chlamydial growth [1,21,32]. The simplest explanation for this
discrepancy is that we measured IFU recovery directly, which is a
more accurate indicator of chlamydial growth and maturation,
whereas others assessed inclusion development by microscopy,
primarily for Ctr [1,32]. With regards to the results of Al-Younes
et al. [21], we suspect that the final concentration of the vehicle
DMSO, rather than BafA1 affected the viability in their assays as
neither we nor others [1,32] have detected such detrimental effects
of BafA1 on cell viability. We observed no overt toxicity of BafA1,
which induces clear dose-dependent responses on chlamydial
growth irrespective of host cell type, without appreciably affecting
host cell survival. Indeed, HEp-2 cells exposed to both 100 nM
BafA1 and cycloheximide were able to support near-normal
growth of Chlamydia – a strong evidence that cell viability was not
compromised by BafA1 treatment. Cytotoxicity was monitored
carefully throughout the duration of the experiments by
microscopy and by FACS analysis using two independent markers
of cell death, annexin V (apoptosis) and propidium iodide (loss of
plasma membrane integrity). The use of three criteria for
cytotoxicity is well beyond what is typically found in scientific
reports that have used BafA1.
In this report, we evaluated the roles of three potential sources
of amino acids – authophagy, the cytosol, and the lysosome, and
we fully acknowledge that there are other sources such as the
proteasome, which we would have included in this investigation.
Unfortunately, we were unable to directly test proteasomal
involvement because blocking its activity for the duration of the
chlamydial developmental cycle results in massive cell death.
Rather, we stress that our data demonstrate that an alternative
source of these nutrients for chlamydiae is the lysosome; with two
distinct species demonstrating a contrasting utilization profile for
this organelle.
Many intracellular bacterial pathogens appear to require
acidification of the endosomal pathway for growth and survival
within the host cell. For example, the growth of Coxiella and
Salmonella is impaired by BafA1 [1,8,48], but, for each of these
pathogens, the vacuole in which they reside is acidified, albeit to
different extents. Acidification may serve as a nutrient source, as a
cue for virulence expression, as an optimal environment for
enzymes adapted to acidic environments, or possibly as some
combination of all three. Brucella requires acidification soon after
uptake by macrophages to activate virulence expression but does
not require it thereafter [9]. Of these pathogens, only Coxiella is an
obligate intracellular pathogen that has undergone extensive
genome reduction leading to similar auxotrophies as Chlamydia
[49]. Thus, it is reasonable that Coxiella would also require the
proteolytic activity of cathepsins as an amino acid source. To our
knowledge, this has not been tested. Indeed, this discovery for
Chlamydia may stimulate more detailed studies on the role of the
lysosome for other intracellular pathogens, especially those that are
auxotrophic for essential amino acids. This report also has
implications on the lysosome being a potential target for antibiotics
given recent evidence that suggests targeting host cell pathways is
an effective antibacterial strategy [50].
Figure 10. Chlamydial acquisition of amino acids. The data support a model where under normal growth conditions, chlamydiae compete
with the host cell for free cytosolic pools of amino acids as well as those produced from lysosomal proteolytic degradation. EBs come pre-equipped
with both amino acid and oligopeptide transporters. Early after infection and differentiation, the RB acquires amino acids likely using oligopeptide
transporters. At later times, Ctr successfully competes with the host cell using its amino acid transporters whereas Cpn continues to rely on
oligopeptide production from the lysosome. BafA1 abolishes lysosomal degradation of proteins. Cycloheximide blocks host cell usage of amino acids,
thus increasing pools of free amino acids and ameliorating the effects of disrupting lysosomal-mediated protein degradation.
doi:10.1371/journal.pone.0016783.g010
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Organisms and cell culture
Chlamydia pneumoniae AR39 EBs were harvested from infected
HEp-2 cell cultures at 35uC with 5% CO2, were purified by
discontinuous density gradient centrifugation in Renografin
(Bracco Diagnostics, Princeton, NJ), and were titered for infectivity
by determining inclusion forming units (IFU). Similarly, EBs were
harvested from Chlamydia trachomatis serovar L2 or B grown at
37uC with 5% CO2. HEp-2 cells were cultivated at 37uC with 5%
CO2 in IMDM supplemented with 10% FBS, 2 mM L-glutamine,
and 10 mg/mL gentamicin (all from Gibco/Invitrogen, Carlsbad,
CA). Bafilomycin A1 and cycloheximide were purchased from
Sigma Chemical Co. (St. Louis, MO) and Cathepsin Inhibitor III
was purchased from EMD Biosciences (San Diego, CA). All other
chemicals were from Sigma unless specified. HEp-2 cells stably
expressing GFP-LC3 were made as described previously [53].
Infection of cells with Cpn and Ctr
HEp-2 cells or MEFs were plated in 6-well culture plates at a
density of 1610
6 cells per well. In a subset of wells, cells were plated
onto glass coverslips for immunofluorescence microscopy. Approx-
imately 18 hr later, confluent cell monolayers were rinsed with
Hank’s balanced salt solution (HBSS; Invitrogen), and, where
indicated, 2 mL inoculum containing 2.6610
6 C p nI F U si nS P G
(0.25 M sucrose, 10 mM sodium phosphate, and 5 mM L-glutamic
acid) wasadded to eachwell. Infectedcellcultures were centrifuged in
a Beckman Allegra 6R centrifuge for 15 min at room temperature,
400 x g then rocked for 15 min at 35uCw i t h o u tC O 2.T h ei n o c u l u m
was aspirated, and fresh supplemented IMDM with or without
inhibitors was added to each well. Infected cultures were incubated at
35uCw i t h5 %C O 2.F o rC t r1 0
6 IFUs (L2) or 2610
6 IFUs (B) were
added directly to each well, and infected cellswere incubated at 37uC
with 5% CO2 unless co-infected with Cpn where they were cultured
at 35uC. For all samples addition of inoculum to wells marks the time
of infection (t=0 hr). For BSA supplementation, cells were infected
with Cpn as above, then incubated in HBSS, HBSS + 5% BSA,
IMDM lacking serum (iIMDM), or normal medium. For Ctr, cells
were pre-starved for 2 hr in HBSS prior to infecting in HBSS, 5%
BSA, iIMDM, or normal medium.
Transfection
5610
4 cells were plated on glass coverslips and allowed to attach
overnight. Cells were transfected with 1 mg of LAMP1-YFP
plasmid (a kind gift of Joel Swanson, University of Michigan) in
Fugene 6 (Roche) according to the manufacturer’s instructions in
Optimem medium (Invitrogen). After 24 hr, cells were treated
with or without 0.1 mM BafA1 for 24 hr. Cells were fixed in 4%
paraformaldehyde in PBS overnight, rinsed, and viewed on an
Olympus Fluoview 500 laser scanning confocal microscope. For
siRNA experiments, cells were transfected with 9 pmol of 3 pooled
Silencer siRNAs against TFEB (Applied Biosystems, Foster City,
CA) or AllStars negative control siRNA (Qiagen) in HiPerFect
Transfection Reagent (Qiagen) according to the manufacturer’s
instructions in Optimem medium. Cells were also mock-
transfected (without siRNA) or left un-transfected as additional
controls. After 20 hr transfection, cells were infected with 1 MOI
of C. trachomatis serovar B in the presence or absence of 0.005 mM
BafA1. At 30 hr post-infection, cells were harvested for IFU and
qPCR analyses (see below).
Quantification of IFUs from infected cell cultures
Medium was aspirated from the infected cells at the indicated
times post-infection (p.i.), and 1 mL (6-well plate) or 250 mL (24-
well plate) of SPG was added to each well. Cells were scraped and
collected from each well into a 1.5 mL microfuge tube with 3 glass
beads. Samples were vortexed for 45 sec and frozen at 280uC.
Samples were titered for infectivity on fresh cell layers as described
above to quantify the number of IFU per well.
Immunofluorescence analyses
For LysoTracker
TM staining, 0.5 mM LysoTracker
TM Red
(Invitrogen) was added directly to live cell cultures. Cells were
incubated for 10 min then washed three times with prewarmed
HBSS, at which point fresh media was added with or without
inhibitors. Confocal fluorescent images were captured on an
Olympus Fluoview 500 Laser Scanning Confocal Microscope.
Flow cytometry
Cells infected with either Cpn or Ctr were trypsinized and
collected at 48 hr p.i. in their culture medium, to preserve any
dead cells that became detached from the culture dishes. Total
cells were counted using a Vi-CELL
TM (Beckman Coulter,
Fullerton, CA)) cell counter system, and 10
6 cells were stained
using an Annexin V-FLUOS staining kit (Roche, Indianapolis,
IN). Total numbers of live (no staining) and dead cells (Annexin V
and/or PI staining) were quantified on a BD Biosciences LSR II
flow cytometer.
qPCR analysis
Total RNA from siRNA transfected, infected cells was collected
as described by Ouellette et al. [46] using Trizol (Invitrogen).
1.5 mg RNA was reverse transcribed using Superscript III RT
(Invitrogen) and random nonamer primers (New England Biolabs,
Ipswich, MA) according to the manufacturer’s instructions. Equal
volumes of diluted cDNA were analyzed for TFEB, Cathepsin D
(CTSD), and 18S rRNA by quantitative PCR using pre-designed
MGB probes (Applied Biosystems) on an ABI Prism 7300
Sequence Detection System (Applied Biosystems). The fold change
in gene expression under each condition was determined by
normalizing TFEB or CTSD expression to 18S rRNA expression
within each sample and comparing to un-transfected cells (DDCT
method).
Electron microscopy analyses
At 24 and 48 hr p.i., for Ctr and Cpn, respectively, cells from
infected cultures were collected and centrifuged to a pellet for
5 min at 250 x g. For co-infection studies, cells were infected with
Cpn as above, grown for 24 hr, then infected with Ctr and treated
with or without BafA1. Cells were incubated for a further 24 hr
prior to processing. Cell pellets were resuspended in 2% EM-grade
glutaraldehyde diluted in PBS, transferred to a microfuge tube,
and centrifuged to a pellet at 250 x g for 5 min. Cells were
subsequently processed for EM as described elsewhere [52].
Briefly, cells were washed three times with PBS then fixed for 1 hr
at room temperature in 1% osmium tetroxide diluted in PBS.
Samples were dehydrated with a graded series of ethanol and
embedded in Spurr’s resin (Electron Microscopy Sciences, Ft.
Washington, PA). 70 to 80 nm sections were cut, stained with
uranyl acetate and lead citrate, and viewed on a Zeiss transmission
electron microscope.
Western blot analysis
At the times indicated, treated and untreated cells were
collected and centrifuged, and protein was extracted from cells
using RIPA buffer. Protein was quantified using a BCA protein
assay (Pierce) according to the manufacturer’s instructions. Equal
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PAGE gel and transferred to nitrocellulose. Western blots were
probed with both primary rabbit anti-LC3 [52] and mouse anti-
actin (Sigma) antibodies. Appropriate secondary HRP-conjugated
antibodies were used (Sigma). Blots were developed using
Immobilon chemiluminescent substrate (Millipore Corp, Billerica,
MA) and exposed to film.
Isolation and culture of Atg7
+/+ and Atg7
2/2 MEFs
Embryos were harvested from timed matings of Atg7
+/2 mice at
embryonic day E14.5 to generate littermate matched Atg7
+/+ and
Atg7
2/2 embryos, and MEFs were isolated and genotyped for Atg7
status as described [38].
Metabolic labeling and uptake of AHA-labeled proteins
For metabolic labeling, infected cells were pre-starved for 1 hr
in DMEM lacking cysteine (cys) and methionine (met). Chlamyd-
iae were metabolically labeled for 8 hr with 50 mM azidohomoa-
lanine (AHA; Invitrogen) in DMEM lacking cys and met
(Invitrogen) and containing 10 mg/mL cycloheximide (Sigma)
and fixed overnight with 4% PFA at 4uC. For uptake of AHA-
labeled proteins, 26175 cm
2 flasks of uninfected cells were first
metabolically labeled for 4 hr as above without cycloheximide.
Cells were collected, centrifuged at 1500 rpm for 5 min at RT,
and re-suspended in 1 mL PBS. Cells were freeze-thawed three
times at 280uC and sonicated twice for 10 s to shear DNA and
solubilize proteins. At 48 hr p.i. for Cpn or 12 hr p.i. for Ctr L2,
the growth medium (IMDM) was removed from infected cells, and
HBSS containing 10% AHA-labeled cell lysate (no cycloheximide)
was added. After 9 hr of feeding, cells were fixed overnight with
4% PFA at 4uC. We tested whether filtration of the cell lysate with
a 10 kDa cut-off filter was necessary to prevent residual AHA
amino acid from labeling inclusions but found no effect. Similarly,
we spiked unlabeled cell lysate with 12.5 mM AHA amino acid but
found no labeling of chlamydiae under these conditions. The
Click-iT Cell Reaction Kit with Alexa555-labeled alkyne (Invitro-
gen) was used according to the manufacturer’s instructions for
visualization of the AHA label. Chlamydiae were subsequently
stained with primary mouse anti-chlamydial Hsp60 antibody and
secondary goat anti-mouse Alexa647 antibody (Invitrogen).
Image Processing
Images from experiments were imported into Adobe Photoshop
CS2 and adjusted equally for contrast.
Statistics
Two-tailed Student t tests assuming equal variance were
performed within each experiment to determine p values
(Microsoft Excel), which were combined for all experiments using
Fisher’s test for combining p values (MStat, University of
Wisconsin, Madison, WI).
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Supporting Information
Figure S1 Expression of TFEB and CTSD over time during
siRNA knockdown experiments. Cells were transfected as
indicated or untransfected (UTD) and total RNA was collected.
Expression of the genes was monitored by qPCR and normalized
to 18S rRNA levels as described in Materials and Methods.
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